RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Institute for Medical Engineering and Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Hum Gene Ther. 2024 Oct;35(19-20):814-824. doi: 10.1089/hum.2024.035. Epub 2024 Jul 3.
Genome editing has the potential to treat genetic diseases in a variety of tissues, including the lung. We have previously developed and validated a dual adeno-associated virus (AAV) CRISPR platform that supports effective editing in the airways of mice. To validate this delivery vehicle in a large animal model, we have shown that intratracheal instillation of CRISPR/Cas9 in AAV5 can edit a housekeeping gene or a disease-related gene in the lungs of young rhesus monkeys. We observed up to 8% editing of in lung lobes after single-dose administration. Single-nuclear RNA sequencing revealed that AAV5 transduces multiple cell types in the caudal lung lobes, including alveolar cells, macrophages, fibroblasts, endothelial cells, and B cells. These results demonstrate that AAV5 is efficient in the delivery of CRISPR/Cas9 in the lung lobes of young rhesus monkeys.
基因组编辑有可能治疗多种组织的遗传疾病,包括肺部。我们之前开发并验证了一种双腺相关病毒 (AAV) CRISPR 平台,该平台支持在小鼠的气道中进行有效编辑。为了在大型动物模型中验证这种输送载体,我们已经表明,气道内给予 CRISPR/Cas9 可以在年轻恒河猴的肺部编辑管家基因或与疾病相关的基因。我们观察到单次给药后,肺叶中的 编辑率高达 8%。单细胞 RNA 测序显示,AAV5 在尾部肺叶中转导多种细胞类型,包括肺泡细胞、巨噬细胞、成纤维细胞、内皮细胞和 B 细胞。这些结果表明,AAV5 能够有效地将 CRISPR/Cas9 递送到年轻恒河猴的肺叶中。